Equities

Mabpharm Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mabpharm Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.40
  • Today's Change-0.03 / -6.98%
  • Shares traded338.00k
  • 1 Year change+21.21%
  • Beta0.8514
Data delayed at least 15 minutes, as of Mar 04 2026 07:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)481.76m
  • Net income in HKD-31.23m
  • Incorporated2018
  • Employees383.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunho Biologics Inc0.00-93.28m961.93m128.00--1.76-----0.6181-0.61810.003.490.00----0.00-14.33---15.84----------6.57--0.1242------39.74------
Brii Biosciences Ltd0.00-426.94m1.05bn96.00--0.3693-----0.5865-0.58650.003.930.00----0.00-14.05-49.92-14.09-54.57-------12,750.27----0.003---100.00---190.66---33.13--
B&K Corp Ltd296.60k-207.53m1.05bn100.00--10.91--3,534.44-1.76-1.760.00250.8165----------------92.34---69,968.59------0.0371---44.70---101.78------
HighTide Therapeutics Inc0.00-330.88m1.11bn57.00--2.79-----0.7319-0.73190.000.69650.00----0.00-49.50---63.55--------------0.2129------59.35------
Kintor Pharmaceutical Ltd12.48m-189.86m1.21bn136.00--4.41--96.68-0.4389-0.43890.02890.54850.019410.661.0674,299.69-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Wuhan YZY Biopharma Co Ltd164.78m-88.68m1.39bn106.00------8.41-0.4575-0.45750.85-0.16090.580511.5413.961,458,228.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
Immunotech Biopharm Ltd0.00-253.99m1.45bn173.00---------0.4538-0.45380.00-0.28910.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
ImmuneOnco Biopharmaceuticls Shanghi Inc127.39m-343.97m1.53bn195.00--2.38--12.02-0.8744-0.87440.32361.490.148--3,865.48816,606.60-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Cloudbreak Pharma Inc78.21m-327.17m1.73bn60.00------22.07-0.39-0.390.0932-3.08------1,533,510.00-------------418.33------19.44------23.40------
Mabpharm Ltd481.76m-31.23m1.77bn383.00--15.7847.873.68-0.0076-0.00760.11680.02720.42090.46594.051,529,387.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Antengene Corp Ltd95.86m-259.78m1.96bn152.00--2.25--20.41-0.418-0.4180.15431.280.06191.513.20567,217.40-16.77-48.14-19.52-53.0678.54---271.00-1,460.934.41--0.2346--36.62--45.07--259.46--
Jiangsu Recbio Technology Co Ltd12.39m-743.11m2.17bn507.00--10.56--175.47-1.56-1.560.02590.42620.006----23,325.33-36.26-31.31-64.03-37.31-----5,990.59--0.2767-100.740.8254------1.67--16.82--
Frontage Holdings Corp1.98bn29.99m2.24bn1.54k74.420.83847.111.130.01480.01480.97421.310.454560.363.971,268,440.000.69023.050.86543.6427.7832.141.526.841.221.970.28610.00-1.9020.48-92.68-46.7213.29--
Hanx Biopharmaceuticals (Wuhan) Co Ltd-100.00bn-100.00bn2.37bn-------------------------------------------------------52.30------
Clover Biopharmaceuticals Ltd58.84m-1.03bn2.39bn243.00------40.59-0.8231-0.82310.0468-1.490.04330.054747.89196,118.20-76.07-75.37---188.1462.57---1,756.85-13,419.000.2541-------2.13---552.11---24.90--
Data as of Mar 04 2026. Currency figures normalised to Mabpharm Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

18.00%Per cent of shares held by top holders
HolderShares% Held
CDH Investment Advisory Pte. Ltd.as of 30 Jun 2025742.35m18.00%
Data from 30 Jun 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.